DEA
| HOME | PRIVACY POLICY | CONTACT US | SITE DIRECTORY |
Skip Navigation

Global News Local News

 News from DEA
   News Releases
   Speeches & Testimony
   Photo Library
   Audio/Video Library
   FOIA

 Briefs & Background
 Drug Trafficking & Abuse
   Drug Information
   Prescription Drug Info.
   Drug Trafficking
   State Factsheets
 Law Enforcement
   Recent Cases
   Major Operations
   Intelligence Reports
   DEA Fugitives
   Training Opportunities
   Statistics
 Drug Policy
   Controlled Substances Act
   Federal Trafficking Penalties
   Drug Scheduling
 DEA Resources
   For Contractors
   For Job Applicants
   For Law Enforcement
   For Legislators
   For Parents & Teachers
   For Physicians/Registrants
   For Students
   For Victims of Crime

 Inside the DEA
   DEA's Mission
   DEA Leadership
   Programs & Operations
   Publications Library
   DEA Museum
   Staffing & Budget
   Office Locations
   DEA History
   DEA Wall of Honor
   Office of Diversion
   Acquisitions & Contracts
   DOJ Homepage


[print friendly page]

LAAM

Closely related to methadone, the synthetic compound levo alphacetylmethadol, or LAAM (ORLMM®), has an even longer duration of action (from 48 to 72 hours) than methadone, permitting a reduction in frequency of use. In 1994, it was approved as a Schedule II treatment drug for narcotic addiction. Both methadone and LAAM have high abuse potential. Their acceptability as narcotic treatment drugs is predicated upon their ability to substitute for heroin, the long duration of action, and their mode of oral administration.

 
www.dea.gov